An internal standard for the quantification of enoxacin
Related Products
Unlabeled Version(s)
16956Enoxacin
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Enoxacin-d8 (hydrochloride)

Item No. 33544

Technical Information
Formal Name
1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl-2,2,3,3,5,5,6,6-d8)-1,8-naphthyridine-3-carboxylic acid, monohydrochloride
CAS Number
2930288-95-0
Molecular Formula
C15H9D8FN4O3 • HCl
Formula Weight
Purity
≥99% deuterated forms (d1-d8)
A solid
DMSO: warmedWater: soluble
SMILES
CCN1C2=NC(N3C([2H])([2H])C([2H])([2H])NC([2H])([2H])C3([2H])[2H])=C(F)C=C2C(C(C(O)=O)=C1)=O.Cl
InChi Code
InChI=1S/C15H17FN4O3.ClH/c1-2-19-8-10(15(22)23)12(21)9-7-11(16)14(18-13(9)19)20-5-3-17-4-6-20;/h7-8,17H,2-6H2,1H3,(H,22,23);1H/i3D2,4D2,5D2,6D2;
InChi Key
ODOAWCIYUUFLHN-JCYLEXHWSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

    Add

    Add

    Add

    Cayman Chemical
    Visit Our Cancer Resource Center
    Find Tools & Resources to Study the Hallmarks of Cancer
    • Cancer cell signaling & regulation
    • Cancer metabolism
    • Tumor microenvironment
    EXPLORE NOW
    Product Description

    Enoxacin-d8 is intended for use as an internal standard for the quantification of enoxacin (Item No. 16956) by GC- or LC-MS. Enoxacin is a fluoroquinolone antibiotic.1,2,3,4 It is active against clinical isolates of a variety of Gram-positive and Gram-negative bacteria, including S. aureus, E. coli, K. pneumoniae, P. aeruginosa, and S. marcescens (MIC50s = 1, 0.12, 0.25, 0.5, and 1 mg/L, respectively).1 Enoxacin inhibits S. aureus DNA gyrase supercoiling activity and topoisomerase IV DNA decatenation (IC50s = 126 and 26.5 µg/ml, respectively).2 It increases survival in mouse models of systemic S. aureus, E. coli, K. pneumoniae, P. aeruginosa, and S. marcescens infection with ED50 values of 15.1, 2.2, 4.1, 120.3, and 7.6 mg/kg, respectively.3 Enoxacin (4 and 8 mg/kg per day) also reduces tumor growth in a 143B human osteosarcoma mouse xenograft model.4 Formulations containing enoxacin have previously been used in the treatment of urinary tract infections and gonorrhea.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Clarke, A.M., Zemcov, S.J., and Campbell, M.E. In-vitro activity of pefloxacin compared to enoxacin, norfloxacin, gentamicin and new β-lactams. J. Antimicrob. Chemother. 15(1), 39-44 (1985).

    2. Takei, M., Fukuda, H., Kishii, R., et alTarget preference of 15 quinolones against Staphylococcus aureus, based on antibacterial activities and target inhibition. Antimicrob. Agents Chemother. 45(12), 3544-3547 (2001).

    3. Ozaki, M., Matsuda, M., Tomii, Y., et alIn vivo evaluation of NM441, a new thiazeto-quinoline derivative. Antimicrob. Agents Chemother. 35(12), 2496-2499 (1991).

    4. Luo, X., Liu, X., Tao, Q., et alEnoxacin inhibits proliferation and invasion of human osteosarcoma cells and reduces bone tumour volume in a murine xenograft model. Oncol. Lett. 20(2), 1400-1408 (2020).